Wolverine Trading, LLC Anavex Life Sciences Corp. Put Options Transaction History

Wolverine Trading, LLC

11 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$4.11 - $7.04 $45,210 - $77,440	11,000 New	11,000 $62,000
Q4 2023 Feb 14, 2024	BUY	$5.04 - $9.95 $68,040 - $134,325	13,500 Added 100.0%	27,000 $251,000
Q3 2023 Nov 15, 2023	SELL	$6.55 - $9.37 $22,270 - $31,857	-3,400 Reduced 20.12%	13,500 $88,000
Q2 2023 Aug 23, 2023	SELL	$7.66 - $9.5 $42,896 - $53,200	-5,600 Reduced 24.89%	16,900 $137,000
Q1 2023 May 15, 2023	SELL	$8.32 - $11.75 $74,048 - $104,575	-8,900 Reduced 28.34%	22,500 $187,000
Q4 2022 Feb 14, 2023	SELL	$7.65 - $14.43 $137,700 - $259,740	-18,000 Reduced 36.44%	31,400 $291,000
Q3 2022 Nov 14, 2022	BUY	$8.9 - $12.86 $253,650 - $366,510	28,500 Added 136.36%	49,400 $482,000
Q2 2022 Aug 15, 2022	SELL	$7.31 - $12.84 $24,854 - $43,656	-3,400 Reduced 13.99%	20,900 $207,000
Q1 2022 May 16, 2022	BUY	$9.74 - $17.69 $236,682 - $429,867	24,300 New	24,300 $298,000
Q4 2021 Feb 14, 2022	SELL	$16.88 - $23.31 $405,120 - $559,440	-24,000 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$16.82 - $25.75 $403,680 - $618,000	24,000 New	24,000 $428,000

154

27.3M

515K

838K

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $581M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Trading, LLC with notifications on news.